We are a new kind of biotech holding and operating company, acquiring and accelerating companies engaged in DEA registered psilocybin, psychoactive compounds, clean label foods, and plant sciences.
Our areas of investment focus.
Psilocybin & Wellness - This includes Empowering Emotional Intelligence through DEA registered Psychoactive Compounds. Learn more
Whole Food - This includes expanding Maui Raw production, innovation and distribution. Learn more
Cannabis | Hemp | CBD - This covers the whole spectrum of products and solutions. Learn more
Why we exist.
Orthogonal exists to empower people to take control of their health and mental wellness. We understand that the future of medicine and food will be fast-tracking development and deployment using technology. Building upon the strength and synergy of the Orthogonal portfolio companies and ecosystem, our next funding round is focusing on one theme: Empowering Health, Mental Wellness and Emotional Intelligence (EI) through Food,
Technology and Psychoactive Compounds. This is our purpose. This is our dharma. Everything we do will align with this vision. We are bringing the 600+ investors from our seed round along this journey. Together, we are elevating and empowering an individual’s overall health and mental wellness in a new Standard of Farma.
What we do.
Over the last ten years, we have acquired and incubated companies bringing the best food, technology and scientific advancements in plant medicine to elevate and empower humanity. Individually, each portfolio company is making a big impact. Collectively, our portfolio companies are shaping a new industry and movement.
There is a rapidly increasing inventory of research papers and abstracts regarding the synthesis the Psilocybin and its analogues or homologues. Advances in the areas of traditional organic chemistry synthesis, bio synthesis and enzymatic synthesis processes are driving this research.
The primary goal of these efforts are to lower the cost of synthesizing psilocybin and other relevant psycho active compounds in order to more broadly study the efficacy of treatment of proposed treatments. Very much similar as advances made in synthesizing antibiotics this century for wider and cost effective distribution. As well as recent advances in the manipulation of yeast and RNA production of THC and CBD products.
The results of this work is being openly published or is easily available via such as National Institute of Mental Health databases in the Untied states and world wide through similar organizations. The rapidly increasing knowledge base regarding the brain chemistry of mental health and wellness are fueling these efforts world wide.
What we are doing?
We continue to identify and align with licensed chemists and labs in the traditional fields of organic and bio chemistry.
Primary goal being to quicken and bring to market so called “1 pot” synthesis of relevant psychoactive materials or compounds. So named “1 pot” synthesis involves combining the fundamental components in simple combinations, adding bio active yeasts, enzymes, bio neutral solvents and allowing the targeted materials to better self organize which require less refinement to purge toxic lab solvents usually used in traditional synthetic lab processes.
We are working to integrate an innovative blend of traditional organic and bio chemistry with new fields of electro and sono chemistry and various non traditional or leading edge extraction and compounding processes to create a cost effective production of psychoactive compounds. The processes manipulates and modifies the ingredients at the molecular level enhancing their bonding efficacy, bio-availability as well as hydrophilic qualities.
Founder & CEO
Linda G. Strause, PhD
Advisor and Partner
Jack Rentz, MD
Jason A. Hobson
Advisor and Partner
Advisor and Partner
Emily Kulpa, PharmD